In recent years, topical steroid withdrawal (TSW) has received greater recognition from research and regulatory agencies. Delphi protocols confirmed the clinical features and treatment options of TSW recognized by physicians. Pilot studies have elucidated the mechanisms of TSW pathology. Regulatory authorities have updated the warning labels of topical corticosteroids (TCS) to include TSW. Some still debate whether TSW is different from the underlying skin diseases caused by TCS exposure. This narrative review analyzes the history of TSW claims and counterclaims from the medical literature. He identifies flaws in skepticism, such as ignoring the syndromic nature of TSW, devaluing patients' symptoms, and circular reasoning about the need for studies. The goal is to help doctors recognize TSW from similar skin manifestations and better inform patients about the risks of TCS.